β-Caryophyllene attenuates dextran sulfate sodium-induced colitis in mice via modulation of gene expression associated mainly with colon inflammation  by Cho, Jae Young et al.
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a  b  s  t  r  a  c  t
We  examined  the  modulatory  activity  of -caryophyllene  (CA)  and  gene  expression  in colitic  colon  tissues
in  a  dextran  sulfate  sodium  (DSS)-induced  colitis  model.  Experimental  colitis  was  induced  by expos-
ing  male  BALB/c  mice to  5%  DSS in  drinking  water  for  7 days.  CA (30  or 300  mg/kg)  was  administered
orally  once  a day  together  with  DSS.  CA  administration  attenuated  the  increases  in the  disease  activ-
ity  index,  colon  weight/length  ratio,  inﬂammation  score,  and  myeloperoxidase  activity  in DSS-treated
mice.  Microarray  analysis  showed  that CA  administration  regulated  the  expression  in colon  tissue  of
inﬂammation-related  genes  including  those  for cytokines  and  chemokines  (Ccl2,  Ccl7,  Ccl11,  Iﬁtm3,  IL-olitis
extran sulfate sodium
ene expression
nﬂammation
1, IL-28,  Tnfrsf1b,  Tnfrsf12a);  acute-phase  proteins  (S100a8,  Saa3,  Hp);  adhesion  molecules  (Cd14,  Cd55,
Cd68,  Mmp3,  Mmp10,  Sema6b,  Sema7a,  Anax13);  and  signal  regulatory  proteins  induced  by  DSS.  CA  sig-
niﬁcantly  suppressed  NF-B  activity,  which  mediates  the  expression  of  a different  set of genes.  These
results  suggest  that CA  attenuates  DSS-induced  colitis,  possibly  by modulating  the  expression  of  genes
associated  mainly  with  colon  inﬂammation  through  inhibition  of DSS-induced  NF-B  activity.
© 2015  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
-Caryophyllene (trans-(1R,9S)-4,11-11-trimethyl-8-
ethylene bicyclo[7.2.0] undec-4-ene; CA) is a major constituent
f many essential oils obtained from a number of plant species such
s Betula (∼30%), Syzygium (∼13%), and Strobilanthes (∼7%) species
2,12,24]. CA shows potential antimicrobial, antioxidant, and anti-
arcinogenic properties [16,19,32] as well as anti-inﬂammatory
ctivity against gastric mucosal injuries and carrageenan- or
rostaglandin E1-induced edema [5,35]. In our previous study, we
emonstrated that CA ameliorated dextran sulfate sodium (DSS)-
Abbreviations: CA, -caryophyllene; CD, crohn disease; Cebpb,
CAAT/enhancer-binding protein &beta; DSS, dextran sulfate sodium; Hp, hap-
oglobin; IBD, inﬂammatory bowel disease; IB, inhibitor B; IL, interleukin; MPO,
yeloperoxidase; NF-B, nuclear factor-kappa B; S100a8, S100 calcium binding
rotein a8; Saa3, serum amyloid A3; SAL, sulfasalazine; TNF-, tumor necrosis
actor-;  UC, ulcerative colitis.
∗ Corresponding author. Fax: +82 31 675 4853.
E-mail address: hschun@cau.ac.kr (H.S. Chun).
ttp://dx.doi.org/10.1016/j.toxrep.2015.07.018
214-7500/© 2015 Published by Elsevier Ireland Ltd. This is an open access article under license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
induced colonic inﬂammation by regulating the proinﬂammatory
cytokine interleukin 6 (IL-6) in BALB/c mice [9]. Following our
study, Bento et al. reported that the anti-inﬂammatory property of
CA is mediated through the activation of the cannabinoid receptor
2 and peroxisome proliferator-activated receptor-, leading to the
inhibition of proinﬂammatory cytokines in DSS-induced ulcerative
colitis model [6].
Inﬂammatory bowel disease (IBD) such as Crohn disease (CD)
and ulcerative colitis (UC) have an unpredictable clinical course
characterized by the involvement of many pleiotropic molecules
that orchestrate both the innate and adaptive immune responses
[8,7]. To understand the genomic changes involved in the patho-
genesis of IBDs, many studies have tried to identify a set of genes
that is expressed distinctively in inﬂamed colonic tissues compared
with normal colonic tissues [11,17,42]. Using a genome-wide cDNA
microarray, [11]. found differences in the gene expression proﬁles
between CD and UC [11]. This ﬁnding suggests that is important to
study the roles of naturally occurring dietary components in regu-
lating the genomic expression in addition to the well-known genes
related to inﬂammation.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1 y Repo
D
i
i
a
i
a
w
o
t
i
D
t
a
e
n
2
2
2
D
s
s
c
u
S
A
f

(
S
2
B
a
l
5
m
w
d
o
w
t
w
o
c
2
m
s
3
s
w
1
s
s
e
s040 J.Y. Cho et al. / Toxicolog
Because of its ability to damage the epithelium and because the
SS-induced colitis animal model mimics the morphology and clin-
cal symptoms of human UC, DSS is the chemical used most often to
nduce colitis [13,26]. cDNA microarray analysis has shown that DSS
ffected the expression of different sets of genes, in particular those
nvolved in the acute inﬂammatory response, leukocyte activation,
nd cell adhesion, proliferation, and differentiation and these genes
ere regulated by the treatment of lactic acid bacteria and xanth-
rrhizol [10,18]. However, the proﬁle of the genes regulated by CA
reatment has not been investigated using transcriptome analysis
n UC colon tissues.
In the present study, we examined the effects of CA in a mouse
SS-induced colitis model. To investigate the molecular targets for
he anti-colitis actions of CA, we used cDNA microarray analysis to
ssess gene expression in colon tissues from these mice. We  also
valuated the possible roles of CA in modulating the upstream sig-
aling mediators such as nuclear factor-B (NF-B) in the RAW
64.7 murine macrophage cell line.
. Materials and methods
.1. Materials and reagents
CA (purity 98%) was obtained from Bordas (Sevilla, Spain), and
SS was obtained from MP  Biomedicals (Solon, OH, USA). Dimethyl
ulfoxide, hydrogen peroxide, lipopolysaccharide (LPS), olive oil,
odium dodecyl sulfate (SDS), and sulfasalazine (SAL) were pur-
hased from Sigma-Aldrich (St. Louis, MO,  USA). Other chemicals
sed were of reagent grade. All primary antibodies including anti-
100 calcium-binding protein a8 (S100a8), anti-serum amyloid
3 (Saa3), anti-haptoglobin (Hp), anti-IL-1, anti-tumor necrosis
actor- (TNF-),  anti-IL-6, anti-CCAAT/enhancer-binding protein
 (Cebpb), anti-phospho-p65-NF-B, anti-phospho-inhibitor of B
IB), anti-actin, and secondary antibodies were purchased from
anta Cruz Biotechnology (Santa Cruz, CA, USA).
.2. Mice and experimental protocol
Six-week-old male BALB/c mice were purchased from Daehan
iolink (Choongchung, Korea) and maintained in a room controlled
t 23 ± 2 ◦C with a relative humidity of 50–55% and a 12/12 h
ight/dark cycle. To induce colitis, the DSS-treated mice were fed
% DSS dissolved in sterile distilled water for 7 days. The control
ice received plain drinking water only. CA (30 or 300 mg/kg body
eight) and a positive drug control, SAL (100 mg/kg body weight)
issolved in olive oil, were administered concomitantly by gavage
nce a day for 7 days. The mice in the control group and colitis group
ere given only the vehicle (olive oil, 0.2 mL/day). Water consump-
ion did not differ between groups in the experiment. This study
as approved by the Institutional Animal Care and Use Committee
f Korea Food Research Institute (#KFRI-M-110006), and animal
are was in accordance with institutional guidelines.
.3. Assessment of colitis
In all mice, a disease activity (DAI) score was determined by
acroscopic examination using the following criteria of [36] with
light modiﬁcation: weight loss score (0, none; 1, 1–5%; 2, 5–10%;
, 10–15%; 4, >15%); diarrhea score (0, normal stool; 1, mildly soft
tool; 2, very soft stool; 3, very soft stool (no regular shape); 4,
atery stool); and bloody feces score (0, normal-colored stool;
, brown stool; 2, brown/red stool; 3, reddish stool; 4, bloody
tool). The colon length and weight were measured, and excised
egments of the colon were then ﬁxed in 10% buffered formalin,
mbedded in parafﬁn, and stained with hematoxylin and eosin. The
amples were evaluated histologically by a pathologist. Neutrophilrts 2 (2015) 1039–1045
inﬁltration into the colon was assessed indirectly by measuring
myeloperoxidase (MPO) activity, as described previously [30]. MPO
activity was  deﬁned as the quantity of enzyme that degraded
1 mol/mL of peroxide at 37 ◦C and is expressed as units/g protein
[20].
2.4. RNA extraction and cDNA microarray
RNA from homogenized colon tissue (n = 3/group) was extracted
and puriﬁed using Qiagen RNeasy mini kits (Qiagen, Valencia,
CA, USA). Puriﬁed total RNA was analyzed using an Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Applied
Biosystems Mouse Genome Survey Arrays (Applied Biosystems,
Foster City, CA, USA) were used to analyze the transcriptional
proﬁles of colon tissue RNA samples. The sequences used for
microarray probe design were from the Celera Genomics Database
(http://www3.appliedbiosystems.com). Digoxigenin-UTP-labeled
cDNA was generated and linearly ampliﬁed from 1 g of total RNA
using an Applied Biosystems Chemiluminescent RT-IVT Labeling Kit
in accordance with the manufacturer’s protocol. Array hybridiza-
tion, chemiluminescence detection, image acquisition, and analysis
were performed using an Applied Biosystems Chemiluminescence
Detection Kit and an Applied Biosystems 1700 Chemiluminescent
Microarray Analyzer. Scanned images were submitted to an Auto-
Grid, and the chemiluminescent signals were quantiﬁed, corrected
for background, and spot and spatially normalized.
2.5. Microarray data analysis and validation
Applied biosystems expression system software was used to
extract the assay signals and determine the signal-to-noise values
from the microarray images. The exported data ﬁle was analyzed
using Avadis Prophetic software (version 4.3; Strand Life Sciences,
Carlsbad, CA, USA). Genes with a minimum p value of 0.05 were
identiﬁed as candidates for signiﬁcantly differentially expressed
genes. To minimize the number of falsely signiﬁcant genes, the
identiﬁed set of genes was ﬁltered by signal-dependent fold-change
thresholds. To calculate the thresholds, the same sample assay sig-
nal ratios were ordered by assay signal intensity and binned in 10
equal sets. Genes having at least 2.0-fold differential expression lev-
els dysregulated by DSS were classiﬁed into functional categories
based on the Gene Ontology database (http://david.abcc.ncifcrf.
gov/) and Mouse Genome Informatics (http://www.informatics.jax.
org/). From these lists, genes regulated by CA were selected using
a 1.5-fold deviation compared with the DSS-treated group.
To validate the microarray data, 500 ng of total RNA were
reverse transcribed to cDNA using the SuperscriptTM II RT-PCR
System (Invitrogen, Karlsruhe, Germany). The reaction mixture
consist of cDNA and 12.5 L of TaqMan Universal PCR Master Mix
(Applied Biosystems). PCR condition were as follows: initial denat-
uration at 95 ◦C for 10 min, followed by 40 cycles of 95 ◦C for 15 s
and 60 ◦C for 1 min  in the ABI PRISM 7900HT Sequence Detec-
tion System (Applied Biosystems, Foster City, CA, USA). All RT-PCR
were performed in triplicate and data were analyzed using the
Sequence Detector software (Applied Biosystems). Relative mRNA
expression levels were calculated for each sample normalized
by reference gene of Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) using the delta–delta Ct method.
2.6. Western blot assay
Colon tissues were homogenized, and the lysates were cen-
trifuged for 20 min  at 12,000 × g at 4 ◦C. Thirty micrograms of
protein was separated by 10% SDS-PAGE and transferred to a
polyvinylidene ﬂuoride membrane. The membrane was incu-
bated with a speciﬁc primary antibody followed by horseradish
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Table  1
Effects of oral administration of CA on symptomatic and histological changes during acute colitis induced by DSS in mice.
Experimental group DAI score Colon Inﬂammation MPO
(0–4) weight/length score (U/g protein)
(mg/cm) (0-4)
CON 0.1 ± 0.0* 43.9 ± 3.4* 0* 1.4 ± 0.2*
DSS 3.1 ± 0.6* 52.1 ± 4.1* 2.9 ± 0.4* 3.0 ± 0.9*
CA30 2.5 ± 0.7* 46.7 ± 3.7* 2.2 ± 0.4* 1.8 ± 0.8*
CA300 2.0 ± 0.8* 44.1 ± 2.8* 2.2 ± 0.5* 1.7 ± 0.5*
SAL100 2.1 ± 0.9* 51.4 ± 4.1* 2.6 ± 0.9* 2.3 ± 0.6*
D
p
a
2
f
2
i
1
C
w
L
w
(
n
t
w
r
O
p
(
p
t
c
t
t
2
l
w
3
3
t
l
c
g
c
i
c
l
b
T
n
a
t
sata are expressed as the mean ± SD.
* p < 0.05 vs. DSS colitis group.
eroxidase-conjugated secondary antibodies and was  then visu-
lized using an ECL system (Amersham, Buckinghamshire, UK).
.7. Cell culture and electrophoretic mobility shift assay
The murine macrophage cell line, RAW 264.7, was obtained
rom American Type Culture Collection (Manassas, VA, USA). Raw
64.7 cells were cultured in DMEM supplemented with 10% heat-
nactivated bovine calf serum (Gibco BRL, Grand Island, NY, USA),
00 units/ml penicillin, and 100 g/mL streptomycin at 37 ◦C in 5%
O2 in an incubator. The cells (1.5 × 105 cells/mL) were pretreated
ith 1–100 M CA for 8 h and then incubated with 500 ng/mL of
PS for 2 h. For electrophoretic mobility shift assay, nuclear extracts
ere prepared using nuclear extraction kits from Panomics Inc.
Fremont, CA, USA). Brieﬂy, cells were lysed with buffer A, the
uclei were pelleted by centrifugation at 14,000 × g for 3 min, and
he nuclei were lysed with buffer B. Following lysis, the samples
ere centrifuged at 14,000 × g for 5 min, and the supernatant was
etained for use in the DNA binding assay and western blot assay.
ligonucleotides containing an NF-B binding site were used as the
robe supplied with the Panomics gel shift kits. Nuclear extracts
10 g protein) were incubated with 1 g of poly[d(I-C)] and DNA
robe in the binding buffer for 5 min  at room temperature. A fur-
her incubation step was performed at 15 ◦C. Protein–DNA binding
omplexes were separated from the free probe using 6% nondena-
uring PAGE. After electrophoresis, the gel was dried and subjected
o autoradiography.
.8. Statistical analysis
The data are presented as the mean ± SD. The data were ana-
yzed using Student’s t test (SPSS Inc., Chicago, IL, USA), and p < 0.05
as accepted as signiﬁcant.
. Results
.1. Effects of CA on DSS-induced colitis in mice
We  ﬁrst conﬁrmed the symptomatic and histological changes in
he DAI, colon weight/length ratio, and MPO  activity (Table 1). Fol-
owing 5% DSS treatment for 7 days, mice exhibited reproducible
olitis characterized by decreased body weight, loose stools, and
ross bleeding. As shown in Table 1, the DAI, which represents the
ombined score for weight loss, stool consistence, and rectal bleed-
ng, was signiﬁcantly higher in the DSS-treated mice than in the
ontrol mice. Animals treated with 30 or 300 mg/kg of CA exhibited
ower DAI scores compared with the mice treated with DSS alone,
ut the difference was signiﬁcant only at the higher dose (p < 0.05).
he colon weight/length ratio, a marker of tissue edema, was sig-
iﬁcantly lower in CA-treated mice than in mice treated with DSS
lone (p < 0.05, Table 1). The inﬂammation score, which reﬂects
he inﬁltration of inﬂammatory cells into both the mucosa and
ubmucosa, was markedly elevated in DSS-treated mice, but wassigniﬁcantly reduced by CA treatment (p < 0.05, Table 1). Represen-
tative photomicrographs of hematoxylin and eosin-stained parafﬁn
sections of colons are shown in Fig. 1. Consistent with the inﬂam-
mation scores, colonic sections in the DSS colitis group showed
typical inﬂammatory changes in colonic architecture such as crypt
and surface epithelial loss as well as inﬁlteration of inﬂammatory
cells (Fig. 1B). These alterations caused by DSS were ameliorated
by the treatment with 30 and 300 mg/kg of CA (Fig. 1C and 1D).
The treatment with DSS alone also increased MPO  activity, an
inﬂammatory marker, in colon tissue. The oral administration of
CA signiﬁcantly inhibited colonic MPO  activity in DSS-treated mice
(p < 0.05, Table 1). Mice treated with the lower concentration of CA
showed signiﬁcant changes in colon weight/length ratio, inﬂam-
mation score, and MPO  activity (Table 1). Oral treatment with SAL,
as a positive drug control, caused signiﬁcant improvement in DAI
score and MPO  activity (p < 0.05), but not in colon weight/length
ratio and inﬂammation score compared with the mice treated with
DSS alone (Table 1).
3.2. Inﬂammation-related genes affected by CA in colon tissue
To assess the proﬁle of molecular markers of inﬂammation in
relation to the attenuation of colitis by CA, mRNA expression and
the protein levels in the colon were assessed on day 7 after the
induction of colitis. In the microarray analysis, genes upregulated
or downregulated by DSS (≥2-fold difference and p < 0.05 between
DSS-treated and control mice) were ﬁrst selected. Twenty-six genes
were identiﬁed and these responsive genes were classiﬁed into four
categories by gene ontology analysis (Table 2). All genes except
Anxa13 were upregulated after DSS exposure for 7 days. Notably,
the mRNA expression of acute-phase proteins such as S100a8, Saa3,
and Hp was increased markedly by >30-fold by DSS. Analysis of the
proinﬂammatory genes showed that those for several C–C motif
chemokine ligands (Ccl2, Ccl7, and Ccl11), cytokines (IL-1 and IL-
28), and TNF family members were also affected by DSS. Increased
expression of CD antigens (CD14, CD55, and CD68), matrix met-
alloproteinases (Mmp3  and Mmp10), and transcription factors
CCAAT/enhancer-binding proteins (Cebpb and Cebpd) were found
in colitic colon tissues. Twenty-six representative inﬂammation-
related genes were effectively modulated by the CA treatment. The
microarray results for the selected genes (S100a8, Saa3, Hp, IL-1,
Mmp3, and Cebpb; marked with an asterisk in Table 2) were vali-
dated using real-time RT–PCR. Although the change ratio of each
transcript was  different, both results of array analysis and real
time RT-PCR showed same alteration tendency for seven genes (Fig.
S1). The expression of IL-6, which has been detected previously in
a DSS-induced colitis model [9], was conﬁrmed by western blot
analysis (Fig. 3). CA administration blocked the expression of six
proteins related to inﬂammation (S100a8, Saa3, Hp, IL-1, TNF-,
and Cebpb) whose expression was  induced by DSS.
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Fig. 1. Representative photomicrographs of hematoxylin and eosin-stained parafﬁn sections of colons (Magniﬁcations, ×100). (A) Control group, (B) DSS colitis group, (C)
CA-treated (30 mg/kg), (D) CA-treated (300 mg/kg).
Table 2
Inﬂammatory and immune response-related gene variations after CA treatment during acute colitis induced by DSS in mice.
Gene Gene DSS CA30 CA300 SAL100
function symbol Fold change p-value Fold change p-value Fold change p-value Fold change p-value
Chemokine/ Ccl2 15.2 ± 1.2 0.000 21.1 ± 0.8 0.000 8.8 ± 0.8 0.000 10.2 ± 1.5 0.003
cytokine Ccl7 10.2 ± 1.6 0.001 5.7 ± 0.8 0.000 2.9 ± 0.9 0.012 6.2 ± 1.2 0.002
Ccl11  3.9 ± 1.2 0.003 3.6 ± 1.1 0.070 2.0 ± 0.8 0.008 3.2 ± 1.2 0.012
Iﬁtm3  4.3 ± 0.9 0.000 1.9 ± 0.5 0.002 1.9 ± 0.7 0.190 4.1 ± 0.9 0.002
IL-1* 9.5 ± 1.2 0.000 3.7 ± 0.6 0.000 5.9 ± 0.8 0.002 5.5 ± 1.4 0.007
IL28  2.5 ± 0.8 0.004 1.7 ± 0.8 0.520 3.3 ± 0.4 0.000 1.7 ± 0.8 0.043
Tnfrsf1b 3.4 ± 0.7 0.000 -1.7 ± 0.6 0.350 1.3 ± 0.5 0.046 2.2 ± 0.7 0.008
Tnfrsf12a 3.2 ± 0.9 0.002 -1.1 ± 0.6 1.000 1.4 ± 0.5 0.025 2. ± 0.7 0.004
Acute  phase S100a8* 147.6 ± 1.7 0.000 112.9 ± 2.3 0.000 71.6 ± 1.2 0.000 33.7 ± 1.9 0.001
protein Saa3* 148.1 ± 2.6 0.000 27.3 ± 2.5 0.001 60.2 ± 2.5 0.000 67.8 ± 2.9 0.001
Hp* 31.5 ± 2.2 0.000 2.7 ± 1.6 0.029 3.6 ± 1.7 0.029 23.5 ± 2.3 0.002
Adhesion Cd14 3.7 ± 1.0 0.001 2.6 ± 0.8 0.002 2.7 ± 0.8 0.001 2.0 ± 0.9 0.020
molecule Cd55 3.1 ± 0.8 0.002 2.5 ± 0.6 0.030 1.9 ± 0.4 0.023 2.0 ± 0.7 0.012
Cd68  2.7 ± 1.4 0.022 -5.4 ± 1.1 0.030 −2.6 ± 0.8 0.029 2.6 ± 1.3 0.030
Mmp3* 18.0 ± 2.0 0.001 4.4 ± 1.2 0.220 4.7 ± 1.1 0.003 12.8 ± 1.5 0.001
Mmp10 13.3 ± 1.8 0.001 8.8 ± 0.9 0.007 8.3 ± 0.9 0.000 8.7 ± 1.7 0.000
Sema6b 2.5 ± 0.5 0.000 1.4 ± 0.5 0.800 1.6 ± 0.4 0.002 1.7 ± 0.9 0.048
Sema7a 4.0 ± 0.8 0.000 1.5 ± 0.6 0.045 2.0 ± 0.6 0.003 2.1 ± 0.9 0.017
Anxa13 -4.1 ± 1.2 0.004 -1.5 ± 0.4 0.920 −1.3 ± 0.4 0.024 -3.9 ± 1.3 0.014
Signal  Bcl3 3.4 ± 0.8 0.000 1.4 ± 0.6 0.032 2.1 ± 0.7 0.032 2.1 ± 0.7 0.007
regulatory Cebpb* 4.1 ± 0.9 0.001 2.7 ± 0.6 0.060 2.0 ± 0.5 0.009 3.2 ± 0.7 0.006
Protein Cebpd 4.7 ± 1.3 0.001 2.4 ± 1.2 0.060 2.2 ± 1.1 0.009 3.4 ± 1.5 0.006
G1p2  7.9 ± 2.3 0.009 1.1 ± 1.4 1.000 3.4 ± 1.2 0.013 6.2 ± 2.4 0.031
Ier3  5.3 ± 1.0 0.000 2.8 ± 0.7 0.080 2.6 ± 0.6 0.001 4.4 ± 1.0 0.003
Inhbb  7.2 ± 1.5 0.002 5.2 ± 0.9 0.003 5.0 ± 1.0 0.004 4.6 ± 1.2 0.004
Ly86  2.5 ± 0.7 0.002 1.7 ± 0.9 0.450 2.5 ± 0.7 0.006 1.9 ± 1.0 0.034
F al con
3
f
eold change are shown by the comparison with the mRNA expression level of norm
* These six genes were validated by a quantitative real-time RT-PCR method.
.3. Inhibition of NF-B activation by CA in vivo and in vitroBecause NF-B is one of the most well-known transcription
actors that can mediate the regulatory effects of CA on gene
xpression in DSS-induced colitis, we used western blot analy-trol mice. Data are represented as the means ± SD.
sis to measure the protein expression of phospho-NF-B  (p65)
and phospho-IB. As shown in Fig. 2A, phospho-NF-B  and IB
proteins were almost undetectable in the colon tissue of normal
control mice. By contrast, the expression of these proteins was
augmented markedly in the DSS-induced inﬂamed colon, and treat-
J.Y. Cho et al. / Toxicology Repo
Fig. 2. Effects of oral administration of CA on protein expression during acute col-
itis induced by DSS in mice. Western blot analysis was performed on colon protein
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axtracts after 7 days of DSS treatment with or without CA (30 or 300 mg/kg): (A)
cute phase proteins; (B) cytokines (C), transcription factor. The results are repre-
entative of at least three independent experiments.
ent with CA inhibited the phosphorylation of NF-B and IB.
e next examined the in vitro NF-B translocation and activa-
ion following treatment with LPS (500 ng/mL) and/or CA in RAW
64.7 cells. The expression of NF-B in the nuclear extract frac-
ion increased following LPS treatment (Fig. 2B, lane 2). However,
n cells treated with CA in the presence of LPS, NF-B expression
ecreased in a dose-dependent manner (Fig. 2B, lanes 3–5). After
reatment with LPS, the DNA binding activity of NF-B was greater
n the nuclear extract fraction than in the control and cold probe-
reated negative control (Fig. 2C, lanes 1 and 2). In cells treated
ith CA in the presence of LPS, the DNA-binding activity of NF-B
ecreased in a dose-dependent manner.
. Discussion
Plant compounds, especially essential oils, are important con-
tituents of fragrances and are used increasingly as essential oils
n the pharmaceutical and food industries [33], and the application
f natural products provides an attractive and relatively nontoxic
lternative for controlling inﬂammatory disorders [31]. A natural
icyclic sesquiterpene, CA is known to exhibit various biological
ctivities and has been granted “generally recognized as safe” sta-
us by the Flavor and Extract Manufacturers Association and is
pproved for food use by the US Food and Drug Administrationrts 2 (2015) 1039–1045 1043
because of its low toxicity [30]. Therefore, it has recently attracted
interest as an effective and safe natural compound for nutraceuti-
cals. Moreover, CA is commonly ingested with vegetable food, and
an estimated daily intake of 10–200 mg of CA could be a dietary fac-
tor with potential to modulate the inﬂammatory signs associated
with colitis [6].
We studied the anti-inﬂammatory activity of CA in a DSS-
induced colitis animal model and identiﬁed the molecular
mediators responsible for its anti-inﬂammatory actions. Oral
administration of CA reduced the severity of acute colonic damage,
as indicated by the DAI score, colon weight/length ratio, and inﬂam-
mation score after 7 days of DSS treatment in mice (Table 1), which
is consistent with those of previous reports [30,23,9]. In the present
study, the main focus was  on the colonic damage induced by DSS.
But several lines of evidences indicate that DSS- induced damage in
mice is not conﬁned to the colon, but also induces morphological
and biochemical changes in the small intestine [43]. In addition,
DSS-treated mice exhibited increased MPO  activity, a marker of
neutrophil inﬁltration and perturbation of the inﬂammatory sys-
tem, which can trigger the pathological responses and symptoms of
colitis [21,29]. CA suppressed MPO  activity, which may have helped
ameliorate neutrophil inﬁltration, as evidenced by the histological
signs of less-severe tissue inﬂammation in colon tissue.
In this study, SAL was used as a positive control and signif-
icantly improved DAI score and MPO  activity. The mechanism
of action of SAL in colitis has not been fully elucidated, but the
5-aminosalicylic acid moiety is considered to have the major
therapeutic action via blocking the production of prostaglandins
and leukotrienes, inhibiting bacterial peptide-induced neutrophil
chemotaxis and adenosine-induced secretion, and scavenging reac-
tive oxygen metabolites [4]. Regarding the intestinal absorption,
SAL is known to be poorly absorbed from the intestine. Compared
to SAL, CA showed superior effects in terms of colon weight/length
ratio and inﬂammation score. Possible explanations for this phe-
nomenon are the differences in the intestinal absorption and
mechanism of action of orally administered SAL and CA. But a
further research is needed to elucidate what the most likely expla-
nation is.
Transcriptome analysis using cDNA microarray has shown that
cytokines, chemokines, adhesion molecules, and acute-phase pro-
teins such as S100a8, Saa3, and Hp play an important role in the
regulation of inﬂammation [10,18,21,37,1,39]. In the present study,
CA treatment suppressed the expression of DSS-induced inﬂam-
matory genes including acute-phase proteins such as S100a8 and
Saa3, proinﬂammatory cytokines such as IL-1 and TNF-, and
adhesion molecules such as Mmp3  and Mmp10 (Table 2). The
acute-phase proteins are involved in triggering an immune reac-
tion in the colon mucosa and in initiating an inﬂammatory response
[10,25]. In particular, S100 calcium-binding proteins S100a6 and
S100a8 have been shown to stimulate the adhesion and migration
of neutrophils [27]. The expression of S100a9 is higher in inﬂamed
human colon tissue than in normal colon tissue [17], which sug-
gests that S100a6 and/or S100a8 may  be molecular markers of
IBDs. Interestingly, CA caused signiﬁcant inhibition of S100a8 in
the microarray analysis, which was  conﬁrmed by real-time reverse
transcription-polymerase chain reaction (RT-PCR) and western blot
analysis (Fig. 1).
Transcriptome expression is mediated by transcriptional regu-
lators and their upstream signaling modulators. NF-B has been
identiﬁed as a key transcription factor involved in the regulation
of genes related to inﬂammation, especially those for cytokines
including IL-1, TNF-, and IL-6, during inﬂammatory processes
including IBD. NF-B is thus considered an ideal target molecule
for the treatment of colitis [22,28]. To provide the possible link
between NF-B activity and the expression of the regulated genes
in the microarray, we investigated the effect of CA on NF-B
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Fig. 3. Effects of CA on NF-B activation during acute colitis induced by DSS in mice
and LPS-induced RAW 264.7 cells. (A) Western blot analysis was performed on colon
protein extracts after 7 days of DSS treatment with or without CA (30 or 300 mg/kg).
(B) RAW 264.7 cells were pretreated with CA (1–100 M)  for 8 h and then stimulated
with LPS (500–ng/mL) for 2 h. NF-B protein was detected in the nuclear faction from
RAW 264.7 cells. (C) DNA binding activity of NF-B was measured by electrophoretic
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Zimmer, M.  Karsak, Beta-caryophyllene is a dietary cannabinoid, Proc. Natl.obility shift assay using the NF-B oligonucleotide. An unlabeled probe was used
s  a control in the competition assay and is indicated as “Cold”.
ctivation in colitic colon tissues induced by DSS and conﬁrmed
n LPS-stimulated murine macrophage RAW 264.7 cells. In DSS-
reated colon tissue, the phosphorylation of IB and NF-B p65
as increased by DSS, indicating the activation of the NF-B sig-
aling pathway, and phosphorylation was blocked by CA treatment
Fig. 2A). The efﬁcacy of CA in regulating NF-B translocation and its
romoter-binding activity was also validated in an in vitro system
Fig. 2B). These results are in agreement with another study using
n experimental colitis model, which showed that the beneﬁcial
ffect of CA was dependent on activation of NF-B [6].
In addition to the common roles of NF-B in inﬂammatory
ytokines, recent studies have reported S100a8/a9-induced NF-
B activation and NF-B-dependent transcription in rheumatoid
rthritis and in colon cancer cells [34,40]. The present study sug-
ests that oral administration of CA effectively suppresses colon
nﬂammation and that the beneﬁcial effect of CA is linked, in
art, to the regulation of NF-B activity and the downstream
nﬂammation-related genes. In addition to the above ﬁndings, the
nvolvement of intestinal epithelial cells [38,3], toll like receptors
41] and transient receptor potential channels [14] in the action of
A on the DSS-induced colitis cannot be ruled out. Furthermore,
15] showed that CA was a selective agonist of cannabinoid recep-
or type-2 (CB2) and exerted cannabimimetic anti-inﬂammatory
ffects in mice. These suggest that further studies are needed to
lucidate the molecular mechanism underlying the action of CA on
he DSS-induced colitis (Fig. 3).
The present study conﬁrmed that CA, given orally, decreased
he DAI score, colon weight/length ratio, histological tissue inﬂam-
ation, and colon MPO  activity in a mouse model of DSS-induced
olitis. In the colitic colon tissue, 26 inﬂammatory genes regulated
[rts 2 (2015) 1039–1045
by CA were identiﬁed and the increase in NF-B activity by DSS  was
signiﬁcantly suppressed by CA. These results suggest that CA atten-
uates DSS-induced colitis in mice and might be a potent natural
treatment for ameliorating IBDs.
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